• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Neurelis closes $114M Series D for diazepam nasal spray

March 10, 2021 By Sean Whooley

NeurelisNeurelis announced today that it closed a $114 million Series D financing round to support its lead orphan drug product.

San Diego-based Neurelis’ Valtoco (diazepam nasal spray) is a proprietary formulation incorporating the science of Intravail transmucosal absorption enhancement technology. The drug enables the noninvasive delivery of a range of drugs, while the company focuses on treating epilepsy.

Valtoco has FDA approval, and the company also received orphan drug exclusivity Valtoco’s intranasal route of administration as “a clinically superior contribution” compared to a rectal gel formulation of the drug that is the standard of care, according to a news release.

In a long-term, open-label, repeat-dose clinical trial evaluating Valtoco in treating more than 4,000 seizures, the drug was generally safe and well-tolerated, the company said.

“We are excited about the immediate and long-term future at Neurelis,” Neurelis president & CEO Craig C. Chambliss said in the release. “We have been able to assemble an impressive leadership team with extensive experience in neurology that has enabled Valtoco’s clinical development, regulatory success, and commercial launch in 2020. Valtoco has become a trusted brand to people with epilepsy.

“This new financing helps us build on a successful foundation as we advance Neurelis as a best-in-class neuroscience company focused on epilepsy. We are grateful to our exceptional investors and look forward to bringing more innovative, life-changing products to the patients who need them.”

In the financing, which will also be used to continue the development and expansion of the company’s neuroscience pipeline, Neurelis said Cormorant Asset Management and Decheng Capital joined existing investors LYZZ Capital and HBM Healthcare Investments. Philos & Partners SA organized other investors, too.

Additionally, the company announced that Alexander Kwit, formerly the EVP of Royalty Pharma, joined the company’s board of directors.

“We are very pleased to have someone with Alex’s background and experience join the Neurelis Board of Directors,” Chambliss said. “His involvement will be extremely valuable as we navigate our path forward and build on our success to date.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Neurological Tagged With: Neurelis Inc.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS